Jeff Goater has sold SURF and made no open-market buys since Jan 2021

Jeff Goater is a biotechnology executive and corporate insider who has served in multiple leadership roles at Surface Oncology, Inc. (SURF), including chief business officer, chief executive officer, and later board director.( At Surface Oncology he led the company’s $120 million initial public offering in April 2018, advanced multiple immuno-oncology programs into clinical trials, grew the organization to roughly 80 employees, and helped secure strategic collaborations, including a major partnership with GlaxoSmithKline.( In his capacity as a director and former CEO, he has been involved in trading Surface Oncology securities as an insider.(

Goater’s career spans more than two decades in biotech and finance, including service as chief financial officer and founding management team member at Voyager Therapeutics, where he played leading roles in its $73 million IPO and a substantial strategic deal with Sanofi, and nearly a decade as a managing director at Evercore, advising on over $100 billion in biopharma transactions.( He currently serves as a partner at The Column Group, holds board and chair roles at several gene therapy and therapeutics companies, and previously began his career as a research scientist in AAV gene therapy, co-authoring numerous peer‑reviewed publications.( Goater is a graduate of the University of Rochester, where he earned a BA in biology, MS degrees in pathology and microbiology/immunology, and an MBA from the Simon Business School.(

Written by Perplexity from public sources.